Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00002026 |
|
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Leukoplakia, Hairy HIV Infections | Drug: Acyclovir | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Primary Purpose: | Treatment |
| Official Title: | Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV) |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Topical antifungal therapy.
Patient must have:
- Newly diagnosed clinical and histological hairy leukoplakia.
- Positive HIV antibody by licensed ELISA or Western blot.
Exclusion Criteria
Co-existing Condition:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Concurrent Medication:
Excluded within 2 weeks of study entry:
- Systemic antifungal treatment.
- Excluded within 6 weeks of study entry:
- Immunomodulators.
- Systemic antiviral treatment.
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Prior Medication:
Excluded within 2 weeks of study entry:
- Systemic antifungal.
- Excluded within 6 weeks of study entry:
- Immunomodulators.
- Systemic antiviral treatment.
- Excluded within 8 weeks of study entry:
- Zidovudine (AZT) or other antiretroviral therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002026
| United States, California | |
| Univ of Southern California / LA County USC Med Ctr | |
| Los Angeles, California, United States, 900331079 | |
Publications:
| ClinicalTrials.gov Identifier: | NCT00002026 History of Changes |
| Other Study ID Numbers: |
033A 179 |
| First Posted: | August 31, 2001 Key Record Dates |
| Last Update Posted: | June 24, 2005 |
| Last Verified: | May 1990 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
AIDS-Related Opportunistic Infections Leukoplakia, Oral Herpesvirus 4, Human Acyclovir AIDS-Related Complex |
Additional relevant MeSH terms:
|
HIV Infections Leukoplakia Leukoplakia, Hairy Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Precancerous Conditions Neoplasms |
Pathological Conditions, Anatomical Epstein-Barr Virus Infections Herpesviridae Infections DNA Virus Infections Leukoplakia, Oral Mouth Neoplasms Head and Neck Neoplasms Neoplasms by Site Mouth Diseases Stomatognathic Diseases Acyclovir Antiviral Agents Anti-Infective Agents |